monitored after endogenous stimulation did not affect the release of cholecystokinin.9 '°Similarly, bombesin" and glucagon'2-'4 have been shown to decrease food intake, but no information is available on the effect of cimetidine or acid reduction on the release of these peptides.
Introduction
In a recent eight week double blind Norwegian trial 60 overweight patients were given 200 mg of cimetidine suspension or placebo 30 minutes before breakfast, lunch, and dinner as adjuvant to a 5 MJ/day (1200 kcal/day) diet supplemented with 9 g of dietary fibre. ' The mean weight loss during cimetidine treatment was 7-4 kg greater during treatment with cimetidine than during placebo (p<0 001) and the perception of hunger, measured on a visual analogue scale, was significantly less at all three meals in the cimetidine group. Furthermore, the reductions of abdominal and hip circumferences, as well as the fall in systolic and diastolic blood pressure, were significantly greater in the patients treated with cimetidine.
The suggested mechanisms of action were a suppression of gastric acid or suppression of hunger by blocking histamine H2 receptors. The impact on appetite might help patients to a better and more prolonged compliance with a restricted diet, leading to greater weight loss.
The double blind principle is of great importance in most therapeutic research, especially when the outcome is subjective or may be influenced by subjective beliefs. However, the effectiveness of the blinding in double blind studies can often be questioned. We therefore did a confirmatory eight week double blind parallel group study with cimetidine. To this first phase we added an eight week crossover or continuation phase to expand on the findings of the previous trial.' Furthermore, we examined the success of the blinding and its relation to weight loss.
Patients and methods
Criteria for entry were age between 18 and 60 years, body mass index between 27 and 39 kg/im, and cooperation and motivation for participation. Criteria for exclusion were obesity due to any endocrinological disorder; history of treatment for depression; evidence of severe somatic or psychiatric disease or alcohol misuse; suspicion of active peptic ulcer; pregnancy, BMJ VOLUME 306lactation, or desire to become pregnant; current or recent energy restricted diet; or administration during the previous three months of any drug which might interfere with cimetidine or disturb the metabolism. The study group comprised 51 women and nine men from the outpatient clinic (table I) , who gave informed consent for a 16 week study of weight loss. Weight was measured to the nearest 0-1 kg with electronic scales (Seca 707, Seca, Copenhagen). Perception of hunger was measured weekly on a visual analogue scale. The waist and hip circumferences were measured with a flexible tape, maintaining close skin contact without compressing underlying tissues. The waist was defined as the circumference located midway between the lower rib margin and the iliac crests. The hip was defined as the widest circumference over the great trochanters.4 Circumferences were obtained with the subjects standing.
Blood pressure was measured in the sitting position after at least 10 minutes' rest. A large cuff (15x43 cm bladder) was used when the overarm circumference exceeded 35 cm; otherwise a normal cuff (12x35 cm bladder) was used.
Blood haemoglobin, serum sodium, potassium, creatinine, alkaline phosphatases, aspartate aminotransferase, blood glucose, and thyroid hormone concentrations were measured before the trial and at weeks 8 and 16. All measurements were made in the hospital's central laboratory by routine methods. The revised Helsinki declaration was observed, and the study was approved by the Copenhagen municipal ethics committee.
STATISTICS
On the basis of a previous study we assumed that diet alone would give a mean loss over eight weeks of 6 (SD 2) kg. To detect an extra loss of 2 kg or more with cimetidine (which we took as being a clinically relevant weight reducing effect) with an a risk of 0 05 (two sided) and a power of 0 90 required 60 patients, allowing for a 30% withdrawal rate.
Student's t test was used to compare mean weight losses, and 95% confidence intervals are given. Nonparametric analyses gave similar results. Statistical significance was taken as p < 0 05.
Multivariate analyses with linear models were used to relate weight loss to drug, trial period, age, sex, and social class. The weight loss was also related to the patients' guesses about treatment, their correctness, and their reasons. The normal approximation to the binomial distribution was used to judge the correctness of the guesses in the two trial periods.5 Paired proportions were compared by the sign test.
Results
The two treatment groups were comparable at baseline (table I) BMJ VOLUME 306 because she became pregnant; the remaining patients were withdrawn because of failure to attend or lack of motivation for continuation of the study. All patients complied with the prescribed medication during both periods. During the first period the mean loss was 5-7 (SD 3 9) kg in the cimetidine group (n=26) and 5 9 (2 5) kg in the placebo group (n=29) (fig 2) . The difference in mean weight loss was insignificant (p= 0-78, 95% confidence interval -2-0 to 1-5 kg) (fig 3) . Mean weight loss in the second period was significantly less than in the first period in all groups (2-1 (-1-2 to 2 9) kg, p<0-0001). No carry over effect was noted (fig 4) . The weight loss during both periods was significantly less in women (7-3 kg) than in men (12-4 kg) (p<0 002), but no differences were found with age or social class. No effect of cimetidine on perception of hunger was seen (data not shown). The patients' body mass index, waist and hip measurements, waist-hip ratio, and systolic and diastolic blood pressures decreased similarly in the cimetidine group and the placebo group during the first period (table II) . Biochemical tests showed no adverse effects from the treatments.
EFFECTIVENESS OF BLINDING
Only four patients had received cimetidine before the trial, and none of them guessed the drug correctly. Correct guesses of the treatment were significantly more prevalent than expected (table III) . There was a non-significant tendency towards more correct guesses during the second period. Of 15 patients who guessed correctly during the first period, only one guessed wrongly in the second, whereas of seven patients who guessed wrongly in the first period, five gave correct guesses in the second (p=0-22 for comparison of the two periods). Improvement in the guesses was not confined to patients whose treatment had changed from the first period. Seven of eight patients who received cimetidine during both trial periods guessed the drug correctly after the second period.
Because of the sex difference in weight loss, only women were included in the multivariate analyses. Guesses were not related to weight loss when all 0- Only side effects reported by one or more patients in the cimetidine group have been included (all 60 patients reported at least one side effect).
guesses were considered or when only correct guesses were included. However, weight losses tended to be high for patients who guessed cimetidine wrongly and low for those who wrongly guessed placebo (table   MV) . After the first period, 11 patients indicated that their suspension tasted like medicine or had side effects. Seven of these patients put forward a guess of their current medication; six guessed cimetidine and one guessed placebo because of lack of effect. All seven guesses were correct (p=0 02). Table V lists the number of patients reporting side effects.
Discussion
In contrast to a recent Norwegian study,' we found no effect of cimetidine on either weight loss or perception of hunger in obese patients. The second phase of the trial, with crossover or continuation of drug treatment, seemed to confirm the inefficiency of cimetidine as adjuvant to a diet in treating obesity (fig 3) .
The Norwegian study included 60 overweight subjects and was a double blind, randomised, placebo controlled trial,' designed like the first period of our study. The cimetidine and placebo suspensions were also identical to those used in our study. However, the BMJ VOLUME 306 24APRIL1993 Weeks FIG 3-Absolute weight loss duringfirst period in the cimetidine group and in the placebo group. Weight loss was identical in the two groups during thefirst week mean weight loss in the Norwegian study was significantly higher in the cimetidine group than in the placebo group (difference=7-3 kg, p <0-001, 95% confidence interval 6-4 to 8 2). A weight reducing effect of 7-3 kg over eight weeks is much greater than that achieved with any other previously tested antiobesity drug.
The second aim of our study was to evaluate the success of the blinding and its relation to weight loss. The double blind, randomised trial is considered the gold standard for therapeutic research.&' In contrast to recommendations,9 '°however, the effectiveness of the blinding has only rarely been tested and related to outcome. In a placebo controlled study of the effect of vitamin C on the common cold, an apparent dose related effect on the duration of symptoms was noted, but the effect disappeared when subjects identifying the vitamin by its special taste were excluded." Our results indicate that unblinding may be particularly likely to invalidate studies with a crossover design. Unfortunately, crossover studies are often insufficiently analysed.'2 13 Since data from the two periods are often pooled, unrecognised bias caused by unblinding during the second period can make the whole study unreliable.
In a study of fenfluramine and placebo in obesity 71% of the patients correctly identified their treatment, most because of side effects of the active drug.'4 Fenfluramine was effective, and there was a tendency towards a greater weight loss in patients taking fenfluramine who gave correct guesses. However, this tendency was also noted for patients receiving placebo. Unfortunately, the number of patients was too small to allow a meaningful comparison of fenfluramine and placebo in this respect, since only three patients taking the drug and three taking placebo guessed wrongly.
We found cimetidine to be inefficient as a treatment for obesity. Despite the fact that the drug had only few side effects, our patients guessed their therapy (cimetidine or placebo) correctly more often than expected by chance, especially during the second period of treatment. Our patients were seen in groups and were able to exchange experiences and suggestions. Therefore, patients obtaining a better than average weight loss would be expected to believe they were being given cimetidine. However, this was not so. The "placebo effect," calculated as the difference in mean weight loss between those who believed they were receiving active treatment and those who believed they were receiving placebo, was insignificant, being only 1 2 kg (-0-8 kg to 3 2 kg). In accordance with international manuscript guidelines'0 we suggest that the success of the blinding be routinely included as an important variable in controlled clinical trials.
Introduction
Paediatric cardiopulmonary arrest is an uncommon occurrence which any doctor may be called on to manage. Oakley reported problems in treating this condition and identified two main factors contributing to delays in making decisions.' The first is the wide variation in the weights of children of different ages, making selection of the correct dose of drug difficult when a child's weight or age is unknown. The second is the infrequency of cardiopulmonary arrest in children, resulting in a tendency for doctors to forget recommended doses. Oakley asked 34 junior doctors of various grades and specialties about their knowledge of doses of drugs, sizes of endotracheal tubes, and defibrillation energy for children of various ages and weights. The results of his study led him to devise a reference chart, which was produced by the BMJ (figure). Although this chart is widely used, no studies evaluating its use have been published.
We have observed the use of the chart in several accident and emergency departments and found the following problems: some of the doses of drugs on the
